Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Long Term Safety of the Sonitus SoundBite System

NCT01108406
Conditions
Hearing Loss, Unilateral Hearing Loss, Total Unilateral Deafness
Interventions
Sonitus SoundBite System, SoundBite Hearing System
Device
Lead sponsor
Sonitus Medical Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Jose, California
Completed Not applicable Interventional Results available

Interaural Frequency and Loudness Mismatch in SSD CI Users

NCT05494632
Conditions
Outcomes
Interventions
Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients., Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients., Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients.
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Partial-thickness Burn
Interventions
KeraStat Gel, Silver Sulfadiazine
Device
Lead sponsor
KeraNetics, LLC
Industry
Eligibility
6 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 4 Interventional Results available

Superficial Partial-Thickness Burn Study

NCT04601532
Conditions
Superficial Partial Thickness Burn
Interventions
Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine
Device · Drug
Lead sponsor
J. Peter Rubin, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Autism Spectrum Disorder, Psychosis, Social Communication
Interventions
PEERS social skills intervention
Behavioral
Lead sponsor
Loma Linda University
Other
Eligibility
12 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention

NCT07743645
Conditions
Prevention, Risk Factors for Mental Illness, Family History of Schizophrenia Spectrum Disorder
Interventions
Psychosocial intervention group
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Second Degree Burn
Interventions
Mepilex, Silvadene
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
5 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Conditions
Covid19, Intellectual Disability, Developmental Disability, Child Development Disorder
Interventions
Standard Messaging, Enhanced Messaging, COVID-19 Testing, Focus Groups, Fuzzy Cognitive Mapping
Behavioral · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 90 Years
Enrollment
1,143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Radiation-Induced Dermatitis
Interventions
Calendula Ointment, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Polyethylene Glycol Hydrogel, Silicone-based Film Forming Topical Gel, Silver Sulfadiazine, Topical Hydrocortisone
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Results available

Ambispective Clinical Evaluation of Sophono™

NCT03143257
Conditions
Conductive Hearing Loss, Single-Sided Deafness, Mixed Hearing Loss
Interventions
Sophono Bone Conduction Hearing Systems
Device
Lead sponsor
Medtronic Surgical Technologies
Industry
Eligibility
5 Years and older
Enrollment
71 participants
Timeline
2017 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 3 more
Conditions
Liver Cirrhosis
Interventions
Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Conditions
Single Sided Deafness
Interventions
SoundBite
Device
Lead sponsor
Sonitus Medical Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Novi, Michigan • San Antonio, Texas
Conditions
Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Interventions
Sensitivity to phonological rules, Sensitivity to semantic category cues.
Other
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
4 Years to 8 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Omaha, Nebraska
Conditions
Schizophrenia
Interventions
TES-TI, Sham TES-TI
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 1Phase 2 Interventional

MRI Sarcoma Non Invasive Thermometry

NCT00093509
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pain
Interventions
SUZ
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Completed Phase 2 Interventional Results available

Blood Lipopolysaccharide (LPS) Rifaximin Study

NCT02124512
Conditions
Obese, Insulin Resistance, Metabolic Syndrome
Interventions
Rifaximin SSD, Placebo
Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Single Sided Deafness, Conductive Hearing Loss
Interventions
SoundBite Hearing System
Device
Lead sponsor
Sonitus Medical Inc
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 4 more
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
90
States / cities
Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more
Conditions
Burn
Interventions
water-soluble therapy, silver sulfadiazine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Charlottesville, Virginia